A monumental challenge for the cure of cancer is complexity. Cancer is comprised of a heterogeneous group of diseases, classified by primary site and histologic type. Complexity of cancer is compounded by marked intertumoral heterogeneity. For example, in colorectal cancer, molecularly defined subgroups identify patients who differ in prognosis and treatment response.1 Further complexity arises from intratumoral heterogeneity and the coexistence of distinct clones.1 No wonder a one-size-fits-all approach to cancer treatment is inadequate, and precision medicine offers great promise.
Nakakura EK. Progress in the March to Precision Cancer Medicine: Left, Right, Left. JAMA Surg. 2018;153(1):67–68. doi:10.1001/jamasurg.2017.3895
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: